FDA Approves Ofev for Progressive Interstitial Lung Diseases
The US FDA has approved Boehringer Ingelheim's Ofev (nintedanib) to treat chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype.
The US FDA has approved Boehringer Ingelheim's Ofev (nintedanib) to treat chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype.